Basal cell carcinoma - Basali Cell Carcinoma
☆ AI Dermatology — Free Service
Ninu awọn abajade 2022 Stiftung Warentest lati Jẹmánì, itẹlọrun alabara pẹlu ModelDerm jẹ kekere diẹ ju pẹlu awọn ijumọsọrọ telemedicine isanwo.
Ninu awọn abajade 2022 Stiftung Warentest lati Jẹmánì, itẹlọrun alabara pẹlu ModelDerm jẹ kekere diẹ ju pẹlu awọn ijumọsọrọ telemedicine isanwo.
Awọn egbo ọgbẹ ti o npa awọ imu ninu agbalagba agbalagba nigbagbogbo ni ayẹwo bi Basali Cell Carcinoma (Basal cell carcinoma). Imu jẹ aaye ti o wọpọ ti iṣẹlẹ fun iru akàn awọ ara.
Basali Cell Carcinoma (Basal cell carcinoma) le ṣafihan pẹlu awọn aala alaibamu ati ọgbẹ.
Carcinoma ti sẹẹli ipilẹ (Basal cell carcinoma) le ṣe aṣiṣe fun wart.
relevance score : -100.0%
ReferencesBasal cell carcinoma (BCC) jẹ iru akàn awọ ti o wọpọ julọ. Ifihan imọlẹ ultraviolet jẹ idi akọkọ. Fere gbogbo awọn ọran BCC ṣe afihan ifihan agbara Hedgehog ti o pọju ninu itupalẹ molikula. Awọn itọju oriṣiriṣi wa ati yan ti o da lori eewu ti nwaye, pataki ti itọju àsopọ, àyànfẹ́ aláìsàn, ati iwọn arun.
Basal cell carcinoma (BCC) is the most common malignancy. Exposure to sunlight is the most important risk factor. Most, if not all, cases of BCC demonstrate overactive Hedgehog signaling. A variety of treatment modalities exist and are selected based on recurrence risk, importance of tissue preservation, patient preference, and extent of disease.
Basal cell carcinoma (BCC) is the most common malignancy. Exposure to sunlight is the most important risk factor. Most, if not all, cases of BCC demonstrate overactive Hedgehog signaling. A variety of treatment modalities exist and are selected based on recurrence risk, importance of tissue preservation, patient preference, and extent of disease.
Basal cell carcinomas jẹ iru arun jejere awọ ti o wọpọ julọ ni awọn agbalagba ti o ni awọ-awọ ti ọjọ-ori 50 ati loke. Nọmba wọn n pọ si ni agbaye, paapaa nitori ifihan si imọlẹ oorun. Awọn ipo jiini kan le jẹ ki eniyan ni itara si idagbasoke awọn aarun wọnyi ni ọjọ-ori ọdọ. Basal cell carcinomas yatọ ni bibo, ti o wa lati irọrun ti o le ṣe itọju tabi awọn ọgbẹ nodular si awọn ti o gbooro sii ti o nilo ijiroro ni awọn ẹgbẹ iṣoogun amọja. Asọtẹlẹ da lori iṣeeṣe ti akàn pada tabi agbara rẹ lati ba ẹran ara wa nitosi. Iṣẹ abẹ jẹ itọju boṣewa fun ọpọlọpọ awọn ọran, aridaju yiyọkuro kongẹ ati awọn aye kekere ti atunwi. Awọn ọna apanirun ti o kere si le ṣe itọju awọn ọgbẹ lasan.
Basal cell carcinomas are the most frequent skin cancers in the fair-skinned adult population over 50 years of age. Their incidence is increasing throughout the world. Ultraviolet (UV) exposure is the major carcinogenic factor. Some genodermatosis can predispose to formation of basal cell carcinomas at an earlier age. Basal cell carcinomas are heterogeneous, from superficial or nodular lesions of good prognosis to very extensive difficult-to-treat lesions that must be discussed in multidisciplinary committees. The prognosis is linked to the risk of recurrence of basal cell carcinoma or its local destructive capacity. The standard treatment for most basal cell carcinomas is surgery, as it allows excision margin control and shows a low risk of recurrence. Superficial lesions can be treated by non-surgical methods with significant efficacy.
Basal cell carcinomas are the most frequent skin cancers in the fair-skinned adult population over 50 years of age. Their incidence is increasing throughout the world. Ultraviolet (UV) exposure is the major carcinogenic factor. Some genodermatosis can predispose to formation of basal cell carcinomas at an earlier age. Basal cell carcinomas are heterogeneous, from superficial or nodular lesions of good prognosis to very extensive difficult-to-treat lesions that must be discussed in multidisciplinary committees. The prognosis is linked to the risk of recurrence of basal cell carcinoma or its local destructive capacity. The standard treatment for most basal cell carcinomas is surgery, as it allows excision margin control and shows a low risk of recurrence. Superficial lesions can be treated by non-surgical methods with significant efficacy.
Itọju akọkọ fun BCC jẹ iṣẹ abẹ. Fun eewu giga tabi BCC loorekoore, pataki ni awọn agbegbe pataki, iṣẹ abẹ iṣakoso micrographically ni a gbaniyanju. Awọn alaisan ti o ni eewu kekere ti BCC superficial le ronu awọn itọju agbegbe tabi awọn ọna iparun. Itọju Photodynamic therapy (Photodynamic therapy) ṣiṣẹ daradara fun superficial ati awọn BCC nodular eewu kekere. Fun locally advanced (locally advanced) tabi BCC metastatic, awọn inhibitors Hedgehog (vismodegib, sonidegib) ni a gbaniyanju. Ti ilosoke arun ba wa tabi aibikita si awọn inhibitors Hedgehog, immunotherapy (immunotherapy) pẹlu anti‑PD1 antibody (cemiplimab) ni a le gbero. Radiotherapy jẹ aṣayan ti o dara fun awọn alaisan ti ko le ni iṣẹ abẹ, paapaa awọn alaisan agbalagba. Electrochemotherapy le gbero ti iṣẹ abẹ tabi radiotherapy kii ṣe aṣayan.
The primary treatment for BCC is surgery. For high-risk or recurring BCC, especially in critical areas, micrographically controlled surgery is recommended. Patients with low-risk superficial BCC might consider topical treatments or destructive methods. Photodynamic therapy works well for superficial and low-risk nodular BCCs. For locally advanced or metastatic BCC, Hedgehog inhibitors (vismodegib, sonidegib) are recommended. If there's disease progression or intolerance to Hedgehog inhibitors, immunotherapy with anti-PD1 antibody (cemiplimab) can be considered. Radiotherapy is a good option for patients who can't have surgery, especially older patients. Electrochemotherapy could be considered if surgery or radiotherapy isn't an option.
The primary treatment for BCC is surgery. For high-risk or recurring BCC, especially in critical areas, micrographically controlled surgery is recommended. Patients with low-risk superficial BCC might consider topical treatments or destructive methods. Photodynamic therapy works well for superficial and low-risk nodular BCCs. For locally advanced or metastatic BCC, Hedgehog inhibitors (vismodegib, sonidegib) are recommended. If there's disease progression or intolerance to Hedgehog inhibitors, immunotherapy with anti-PD1 antibody (cemiplimab) can be considered. Radiotherapy is a good option for patients who can't have surgery, especially older patients. Electrochemotherapy could be considered if surgery or radiotherapy isn't an option.
Awọn okunfa ewu pẹlu ifihan si ina ultraviolet, itọju ailera itansan, ifihan igba pipẹ si arsenic ati iṣẹ eto ajẹsara ti ko dara (fun apẹẹrẹ gbigbe ara eniyan). Ifihan si ina UV lakoko ọmọde jẹ ipalara paapaa.
Lẹhin ṣiṣe ayẹwo nipasẹ biopsy, itọju jẹ igbagbogbo nipasẹ yiyọkuro iṣẹ abẹ. Eyi le jẹ nipasẹ ilọkuro ti o rọrun ti akàn ba kere; Ti akàn ko ba kere, iṣẹ abẹ Mohs ni a ṣe iṣeduro ni gbogbogbo.
Basal cell carcinoma jẹ o kere ju 32% ti gbogbo awọn aarun ni agbaye. Ninu awọn aarun awọ ara miiran ju melanoma, nipa 80% jẹ awọn aarun sẹẹli basal. Ni Orilẹ Amẹrika, nipa 35% ti awọn ọkunrin funfun ati 25% ti awọn obinrin funfun ni o ni ipa nipasẹ basal cell carcinoma ni aaye kan ninu igbesi aye wọn.
○ Ayẹwo ati Itọju
#Dermoscopy
#Skin biopsy
#Mohs surgery